Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
ZNTL compared with LPCN: revenue, margins and what each company keeps, and the suppliers and customers both name
ZNTL
Zentalis Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
LPCN
Lipocine Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
ZNTL
Zentalis Pharmaceuticals, Inc.
vs
LPCN
Lipocine Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
ZNTL: latest quarter is a loss; flow not drawable. LPCN: latest quarter is a loss; flow not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
ZNTL, solid
LPCN, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only ZNTL
5
PFE
Pfizer
supplier
IMNM
Immunome
customer
GSK
GSK
supplier
—
Dana‑Farber Cancer Institute
unlisted
supplier
1 more · ZNTL chain
›
Shared
0
No disclosed counterparties: LPCN.
Only LPCN
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
ZNTL
Zentalis Pharmaceuticals, Inc.
Change
1.94
· pre 1.94
· delayed
Mkt cap
$140.5M
Revenue
$27M
Q4 FY24
Revenue
—
LPCN
Lipocine Inc.
Change
1.44
· pre 1.43
· delayed
Pre-market
Oct 30 '26
delayed
Mkt cap
$11.9M
Revenue
$190,099
Q2 FY26
Revenue
$2M
FY25
vs
Compare
Pre-market
Oct 30 '26
delayed
ZNTL
Zentalis Pharmaceuticals, Inc.
vs
LPCN
Lipocine Inc.
1.94
pre 1.94
delayed
Price
1.44
pre 1.43
delayed
$140.5M
Mkt cap
$11.9M
Q4 FY24
$27M
Revenue
$190,099
Q2 FY26
—
Revenue
$2M
FY25
Change
Change
ZNTL
1.94
vs
LPCN
1.44
Pre-market
Oct 30 '26
delayed